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ABSTRACT 26 
Objective: To investigate the influence of habitual caffeine intake on aerobic exercise performance responses 27 
to acute caffeine supplementation. Methods: A double-blind, crossover, counterbalanced study was performed. 28 
Forty male endurance-trained cyclists were allocated into tertiles according to their daily caffeine intake: low 29 
(58 ± 29 mg.d-1), moderate (143 ± 25 mg.d-1), and high consumers (351 ± 139 mg.d-1). Participants completed 30 
three trials in which they performed simulated cycling time-trials in the fastest time possible following 31 
ingestion of: caffeine (CAF: 6 mg.kg-1 BM), placebo (PLA), and no supplement (CON). Results: Mixed-model 32 
analysis revealed time-trial performance was significantly improved in CAF compared to PLA and CON 33 
(29.92±2.18 min vs 30.81±2.67 and 31.14±2.71 min; P = <0.0002). ANCOVA revealed no influence of 34 
habitual caffeine intake as a covariate on exercise performance (P=0.47). Time-trial performance was not 35 
significantly different between tertiles (P=0.75). No correlation was observed between habitual caffeine intake 36 
and absolute changes (CAF – CON) in time-trial performance with caffeine (P=0.524). Individual analysis 37 
showed that eight, seven and five individuals improved above the variation of the test in CAF in the low, 38 
moderate and high tertiles, respectively. A Fisher's Exact Test did not show any significant differences in the 39 
number of individuals who improved in CAF between the tertiles (P>0.05). Blood lactate and ratings of 40 
perceived exertion were not different between trials and tertiles (P>0.05). Conclusion: Performance effects of 41 
acute caffeine supplementation during a ~30 min cycling TT performance were not influenced by the level of 42 
habitual caffeine consumption. 43 
 44 
Keywords: supplement; daily consumption; endurance; time-trial. 45 
 46 
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 48 
New & Noteworthy 49 
 There has been a long-standing paradigm that habitual caffeine intake may influence the ergogenicity of 50 
caffeine supplementation. 51 
 Low, moderate and high caffeine consumers showed similar absolute and relative improvements in cycling 52 
time-trial performance following acute supplementation of 6 mg.kg-1 BM caffeine. 53 
 Performance effects of acute caffeine were not influenced by the level of habitual caffeine consumption, 54 
suggesting that high habitual caffeine intake does not negate the benefits of acute caffeine supplementation. 55 
 56 
 57 
 58 
 59 
 60 
 61 
 62 
 63 
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 65 
 66 
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 68 
 69 
 70 
 71 
 72 
 73 
 74 
INTRODUCTION 75 
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 76 
 The most consumed psychoactive substance worldwide, caffeine, is a xanthine-derived alkaloid (1,3,7-77 
trimethilxanthine) naturally found in common dietary products, such as coffee, green-tea extracts, chocolate, 78 
and soda.(8) Ingestion of 5-6 mg·kg-1BM caffeine results in peak plasma caffeine concentrations of 30-49 79 
µmol·L-1 within 40 to 60 minutes,(17) and its half-life may vary from 3 to 6 hours.(5) Caffeine use in sports is 80 
highly prevalent and supported by meta-analytic data, which has been shown that a median dose of 6 mg·kg-81 
1BM 60 min before exercise h improves performance (+1.9%; 95% CI: 0.01% to 3.8%) during both endurance 82 
and high-intensity exercise protocols.(11) 83 
 The exact mechanisms by which caffeine exerts its ergogenic effects are still under debate, with 84 
suggested mechanisms including fatty acid mobilization and oxidation, endogenous glycogen content sparing, 85 
calcium ion release from the sarcoplasmic reticulum and potassium ion attenuation in the interstitium (for 86 
reviews see. (16, 24) However, its ergogenic effects are most likely due to its ability to act as an adenosine A1 87 
and A2A receptor antagonist, ultimately resulting in increased dopamine and noradrenaline release, thereby 88 
promoting feelings of wakefulness and alertness, and decreasing the rate of perceived exertion and pain during 89 
exercise.(27) Regular consumption of caffeine has been associated with an upregulation of the number of 90 
adenosine receptors in vascular and neural tissues of the brain.(12, 13) Based on these observations, it could be 91 
speculated that habitual and non-habitual caffeine consumers would respond differently to caffeine 92 
supplementation during exercise. Indeed, Beaumont, et al.(4) recently demonstrated that 4 weeks of caffeine 93 
ingestion (1.5 – 3.0 mg·kg-1·day-1) resulted in an increased tolerance to acute caffeine supplementation in 94 
previously low habitual caffeine consumers, with the ergogenic effect of acute caffeine supplementation no 95 
longer apparent. Based upon these data, it appears reasonable to assume that individuals with different levels of 96 
long-term habitual caffeine consumption (i.e., low, moderate or high) may also show differences in the 97 
ergogenic response to acute caffeine supplementation.  98 
 Studies directly addressing the relationship between habitual intake of caffeine and the effect of caffeine 99 
supplementation on exercise performance are inconsistent. Dodd, et al.(10) showed no differences in the effects 00 
of caffeine on exercise performance between caffeine naïve individuals and habitual consumers. Conversely, 01 
Bell & McLellan(5) demonstrated that non-habitual caffeine consumers cycled longer than habitual consumers 02 
during a cycling-to-exhaustion protocol at 80% VO2max following acute caffeine ingestion. These studies are 03 
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inconclusive due to several factors including their binary stratification of subjects as habitual (> 300 mg·day-1) 04 
or non-habitual consumers (< 50 mg·day-1), disregarding intermediary intakes. Moreover, these studies enrolled 05 
a relatively low total number of subjects (n < 21), hampering definitive conclusions. Finally, to assess 06 
performance, time-to-exhaustion tests were employed, which have been subjected to criticisms due to poor 07 
external validity and large variability.(9, 20) Notwithstanding the lack of solid evidence, there is a belief that 08 
individuals who have a low caffeine consumption may have greater performance improvements following acute 09 
caffeine supplementation than those who have a high caffeine consumption, which has led to practical 10 
recommendations such as removing/reducing caffeine from the diet before supplementing with caffeine for 11 
sports competition.(31) 12 
 In light of these contrasting data, this study aimed to investigate whether the long-standing notion holds 13 
true that habitual intake of caffeine (i.e., low, moderate, and high) influences the effects of acute caffeine 14 
supplementation on exercise performance using a large sample of volunteers and a reliable endurance exercise 15 
protocol. We hypothesized that habitual caffeine intake would influence the ergogenic effects of caffeine 16 
supplementation, with greater aerobic exercise performance gains in individuals with lower regular 17 
consumption.  18 
 19 
 20 
21 
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MATERIALS AND METHODS 22 
 23 
Participants 24 
 25 
Forty-two recreationally-trained male cyclists, out of 125 screened, participated in this study, although 26 
only forty were included in the analysis since one individual did not complete the habitual intake form and 27 
another did not complete all exercise trials for reasons unrelated to the study. All of them were competitive 28 
cyclists at either amateur or professional level, trained at least 4 times/week, and cycled over 150 km/week. The 29 
exclusion criteria included the use of any dietary supplement (except carbohydrate and proteins) for at least 6 30 
months prior to the study, and any prior use of anabolic steroids. Participants were fully informed of the nature 31 
and possible risks of the experimental procedures before their written consent was obtained. The study was 32 
approved by the University of São Paulo’s Ethics Review Committee as part of a larger thematic project, the 33 
remaining data of which are reported elsewhere (Saunders et al., in press).(30) 34 
 35 
Experimental design 36 
 37 
This was a double-blind, counterbalanced, crossover study. Participants underwent three experimental 38 
trials: caffeine supplementation (CAF), placebo supplementation (PLA) and no supplement (CON). The 39 
experimental sessions were performed on different days at least 7 days apart. Participants were randomly 40 
assigned to the experimental trials using a Latin Square model.(25) 41 
Participants visited our laboratory on six separate occasions. On the first day, height and body mass 42 
were measured, and individuals responded to a validated Food Frequency Questionnaire (FFQ) to assess 43 
habitual caffeine intake. Thereafter, a maximal incremental test was performed to determine VO2max. On days 2 44 
and 3, familiarizations to the main exercise test were performed. On days 4, 5, and 6, participants engaged in 45 
the main experimental trials, which consisted of a simulated cycling time-trial (TT) performed on an 46 
electronically braked cycle ergometer (Lode Excalibur, Groningen, The Netherlands). All exercise tests were 47 
individually standardized to be carried out at the same time of day following a 6-h fasting period and 60-min 48 
after supplement ingestion.  49 
 by 10.220.33.3 on M
ay 16, 2017
http://jap.physiology.org/
D
ow
nloaded from
 
To tightly control this study, participants were instructed to abstain from training, alcohol and caffeine-50 
containing substances within the 24-h period prior to the experimental sessions. Participants were also asked to 51 
record a 24-h food recall before each test, from which carbohydrate, protein, fat and caloric intake were 52 
calculated. To assist the participants in refraining from dietary caffeine, they were provided with a 53 
comprehensive list of the main products containing caffeine. Additionally, the participants were given a book 54 
with instructions and illustrative examples on how to fill out the dietary recall. The food recalls were analyzed 55 
before each experimental session by a member of our team to ensure that participants did not consume any food 56 
or beverage containing caffeine.  57 
To test the influence of habitual caffeine intake on the exercise responses to acute caffeine 58 
supplementation, participants were allocated into tertiles according to their dietary intake of caffeine using 59 
statistical software (STATISTICA v.10; StatSoft, Tulsa, USA). This resulted in the following sub-groups: low 60 
consumers (58 ± 29 mg·day-1; range = 2 to 101 mg·day-1; 95% CI: 44.2 – 71.7; n = 14), moderate consumers 61 
(143 ± 25 mg·day-1; range = 104 to 183 mg·day-1; 95% CI: 130.1 – 155.9; n = 12), and high consumers (351 ± 62 
139 mg·day-1; range = 190 to 583 mg·day-1; 95% CI: 285.2 – 416.8; n = 14) (Table 1).  63 
 64 
            Maximum oxygen consumption and workload capacity 65 
 66 
 Participants performed a graded exercise test on a cycle ergometer (Lode Excalibur, Groningen, The 67 
Netherlands) to determine VO2max. Individual seat and handlebar position were recorded and replicated for each 68 
subsequent visit. Participants began pedaling at a power output of 75 W, with 50 W increments every 4 min for 69 
four submaximal stages. Thereafter, work rate was increased by 30 W every minute until volitional exhaustion. 70 
The last completed stage plus the fraction of time spent in the final non-completed stage multiplied by 30 W 71 
was defined as an individual’s power max (Wmax). Heart rate (HR) was monitored every minute using a 72 
transmitter/telemetry unit (Polar System, Finland). Pulmonary gas exchange was determined breath by breath 73 
for O2 and CO2 concentrations and minute ventilation by use of a portable gas analysis system (K4 b2, Cosmed, 74 
Rome, Italy). The gas analyzer was calibrated immediately before and verified after each test by using a 75 
certified gravimetric gas mixture (BOC Gases, Chatswood, Australia). The ventilometer was calibrated pre-76 
 by 10.220.33.3 on M
ay 16, 2017
http://jap.physiology.org/
D
ow
nloaded from
 
exercise and verified post-exercise using a 3-liter syringe in accordance with the manufacturer’s instructions. 77 
There were no significant differences between pre- and post-test calibrations for any test. 78 
  79 
           Simulated cycling time-trial 80 
 81 
 Participants reported to the laboratory at individually standardized times after a 6-h fasting period. Prior 82 
to the main exercise, participants underwent a 5-min warm-up at 125 W, immediately followed by the 83 
simulated cycling km TT, which has been shown to be reliable for recreationally-trained cyclists following a 84 
familiarization session (CV = 2.9%, intraclass correlation = 0.87 [0.67 – 0.95], smallest meaningful change = 85 
4.8 W; Oliveira et al., in press).(28) Participants were required to perform a set amount of work (mean: 420 ± 86 
69 kJ) in the shortest time possible. Individual total work to be performed was calculated according to the 87 
equation of Jeukendrup, Saris, Brouns, and Kester, 1996:(22)  88 
 89 
 Total amount of work = 0.85 x Wmax x 1800 90 
 91 
Where Wmax is the maximal workload capacity determined at day 1 and 1800 is duration in seconds 92 
(equivalent to 30-min). The ergometer was set in linear mode so that 85% Wmax was obtained when the 93 
participants cycled at 95 rpm. The participants were kept unaware of performance-related information (exercise 94 
time and cadence) during the tests. The only information the participants received during the test was the 95 
percentage of work performed relative to the preset task, namely following 25, 50, 75, 90 and 100% completion 96 
of the total work done (%TWD). At these set intervals during the trial, participants were asked to rate their 97 
perceived exertion (RPE) using the 6- to 20-point Borg scale(6) and a fingertip blood sample was collected for 98 
the analysis of lactate. A small aliquot (20 μL) of blood was taken and homogenized in a microtube containing 99 
the same volume of an ice-cold 2% NaF solution. Samples were centrifuged at 2000 g for 5 min at 4oC to 00 
separate plasma from erythrocytes. Plasma was removed and stored at -80 oC until analysis. Plasma lactate was 01 
determined spectrophotometrically using an enzymatic-colorimetric method as supplied by a commercially 02 
available kit (Katal, Interteck, Sao Paulo, Brazil).No encouragement was provided during the tests. Finally, all 03 
persons not involved in the study were excluded from the laboratory to prevent any external disruption. 04 
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 05 
Supplementation protocol 06 
 07 
The participants received a dose of anhydrous caffeine (6 mg·kg-1BM) or placebo (dextrose) provided in 08 
gelatin capsules identical in color, size and appearance. No substance was administered in CON. The capsules 09 
were ingested with ad libitum water intake 60-min before the exercise tests. Participants rested quietly for 60-10 
min before starting the test in all session. Supplements for each participant were prepared and separated by a 11 
non-affiliated researcher to ensure double-blinding.  12 
 13 
Caffeine and food intake assessments 14 
 15 
Habitual caffeine intake was assessed by a specific FFQ adapted from a previously validated 16 
questionnaire(7) under the supervision of a qualified nutritionist. The questionnaire was employed to assess the 17 
habitual consumption of dietary products rich in caffeine. Portions, in household measures, were used to assess 18 
the amount of food consumed according to the following frequency of consumption: a) more than three times a 19 
day, b) two to three times a day, c) once a day, d) five to six times a week, e) two to four times per week, f) 20 
once a week, g) three times per month, h) rarely or never. The list was composed of 10 dietary products with 21 
high caffeine content, according to the Food and Drug Administration(32), namely: a) espresso and espresso 22 
drinks, b) brewed coffee, c) instant coffee, d) green tea, e) black tea, f) energetic drinks, g) regular and diet 23 
colas drinks, h) dark and milk chocolates, i) sweet cocoa powder, and j) caffeine supplements. Where possible, 24 
exact brands of products consumed were identified and subsequent caffeine content of these products obtained. 25 
Previously published nutritional tables were used for database construction.(8, 32) Food intake was assessed by 26 
means of six 24-h dietary recalls recorded before the exercise sessions (one VO2max test, two familiarization 27 
sessions and three main trials). Energy and macronutrient intake were analyzed by the software Avanutri online 28 
(Avanutri, Rio de Janeiro, Brazil).  29 
 30 
Statistics 31 
 32 
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Data are presented as mean ± standard deviation (with 95% confidence intervals - CI) and were analysed 33 
using SAS statistical software (v. 9.3). Statistical significance was accepted at P ≤ 0.05. Mixed-model analyses 34 
with repeated measures were used to compare the overall effect of caffeine on time-trial performance (TT 35 
performance) as well as to compare the food consumption between experimental trials; Trial (CON, PLA and 36 
CAF) was used as a fixed factor and participants as a random factor. A mixed-model was used to analyse the 37 
overall effect of caffeine on RPE and lactate, where Trial (CON, PLA and CAF) and %TWD (0, 25, 50, 75, 90 38 
and 100%) were considered fixed factors.  39 
The absolute changes in TT performance were also analysed using a mixed-model analysis of 40 
covariance (ANCOVA) assuming habitual caffeine intake as a covariate, Trial (CAF and PLA) as a fixed factor 41 
and participants as a random factor. A further mixed model was employed to examine the influence of habitual 42 
caffeine intake (i.e., Consumption) on the absolute changes in TT performance (i.e., CAF – CON and PLA – 43 
CON) in response to supplementation, where Consumption (low, moderate and high) and Trial (PLA and CAF) 44 
were fixed factors. A Kenward-Roger correction was used to account for this unbalanced design and make 45 
approximate inferences about these fixed effects in a mixed linear model. Tukey-Kramer adjustments for 46 
multiple comparisons were performed whenever a significant F-value was obtained. The abovementioned 47 
inferential analyses were also performed having the subjects divided into tertiles according to their habitual 48 
caffeine intake relative to body weight. However, we opted for not reporting these data as i) results were 49 
virtually the same despite the correction for body weight; and ii) literature commonly presents habitual caffeine 50 
intake as absolute values,(5, 10) thus facilitating the contrast of findings.     51 
Pearson’s correlation was performed between habitual caffeine intake and the absolute change in TT 52 
performance. Magnitude based inferences (MBIs) were used to determine the practical significance of caffeine 53 
on TT performance using a spreadsheet to establish the likelihood of a meaningful effect on exercise 54 
capacity.(3) The smallest worthwhile improvement in time to completion was 36 s, equivalent to half the 55 
unbiased typical error associated with the measurement based upon the reliability data from 50 individuals. 56 
Qualitative descriptors were assigned to the positive percentile scores as follows: <1%, almost certainly not 57 
beneficial; 1-5%, very unlikely beneficial; 5-25%, unlikely beneficial; 25-75%, possibly beneficial; 75-95%, 58 
likely beneficial; 95-99%, very likely beneficial; > 99%, almost certainly beneficial.(19) A Fischer Exact test 59 
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was used to determine any differences in i) supplement identification between trials, and ii) the proportion of 60 
individuals who improved in CAF between tertiles. 61 
 62 
RESULTS 63 
 64 
Overall effect of caffeine on TT performance, RPE and plasma lactate concentrations 65 
Three outliers were visually identified using boxplot analysis; each of these individuals had a 66 
performance change in excess of 16% in CAF (two improved, one worsened). Thus, we performed all analyses 67 
both with, and without, these three participants. Since the main outcomes remained the same, we decided to 68 
only report the analyses with all individuals.  69 
 No order effect was shown (F = 0.781; p = 0.461). There was a main effect of Trial on TT performance 70 
(F = 9.472; P = <0.01) (Figure 1A), with post-hoc tests revealing that performance in CAF was significantly 71 
improved compared to PLA (+2.4 ± 5.5%; P = 0.01; 95% CI = -93.3 to -3.3 s; 78% likely beneficial) and CON 72 
(+3.3 ± 6.4%; P = <0.008; 95% CI = -111.4 to -21.3 s; 92% likely beneficial). No significant difference in 73 
performance was shown between PLA and CON (+0.8 ± 6.3%; P = 0.62; 95% CI = -63.1 to 26.9 s; 18% 74 
unlikely beneficial).  75 
There was no main effect of Trial (F = 0.22; P = 0.805) on RPE, but there was a significant main effect 76 
of %TWD (F = 118.08; P < 0.0001); RPE increased throughout the exercise test although there were no 77 
differences at any time point between CAF, PLA and CON (Figure 1B).  78 
No main effect of Trial (F = 1.44; P = 0.240) on plasma lactate concentrations was observed, although 79 
there was a significant main effect of %TWD (F = 69.42; P < 0.0001); plasma lactate significantly increased 80 
with exercise compared to rest and post-ingestion for CAF, PLA and CON, although no differences at any time 81 
point were observed between the trials. Nevertheless, a significant within-group increase was observed for CAF 82 
at 100% compared to the previous time points (i.e., 0, 25, 50, 75, and 90%; all P < 0.05) (Figure 1C). 83 
 84 
 85 
Influence of habitual caffeine intake on TT performance, RPE and plasma lactate concentrations in 86 
response to acute caffeine supplementation 87 
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 88 
ANCOVA analysis showed no significant effect of habitual caffeine intake as a covariate (F= 0.54, P = 89 
0.47). There was no Consumption x Trial interaction effect on absolute TT performance (F = 0.47; P = 0.756) 90 
(Figure 2A), or on TT performance when CAF and PLA data were treated as absolute change compared to 91 
CON (F = 1.64; P = 0.207). The absolute difference between CAF and CON was not significantly different 92 
between tertiles (low vs moderate: P = 1.000; low vs high: P = 0.996; moderate vs high: P = 0.986) (Figure 93 
2B), nor was the difference between CAF and PLA (data not shown).  94 
MBIs suggested possible to likely improvements in CAF in the tertiles (Table 2). Individual analysis 95 
showed that eight, seven and five individuals improved above the variation of the test with CAF compared to 96 
CON in low, moderate and high, respectively (Figure 3), and a Fisher's Exact Test did not show any significant 97 
differences in the number of individuals who improved between the tertiles (P > 0.05). There was no 98 
correlation between habitual caffeine intake and absolute difference (i.e., CAF – CON) in performance (Figure 99 
4).  00 
No main effect of Consumption (F = 0.63; P = 0.538) or interaction effects (Consumption x Trial x 01 
%TWD - F = 0.58; P = 0.945) were observed for RPE between tertiles (data not shown). In addition, no main 02 
effect of Consumption (F = 0.77; P = 0.470) or interaction effects (Consumption x Trial x %TWD - F = 1.02; P 03 
= 0.437) were detected for plasma lactate concentrations (data not shown). 04 
 05 
Food consumption analysis 06 
  07 
As expected, tertiles differed significantly in their habitual caffeine intake (P = 0.0001) (Table 1). No 08 
significant differences for protein, carbohydrate, fat or caloric intake were observed between low, moderate and 09 
high caffeine consumers before CAF, PLA and CON (Table 3). 10 
 11 
Side effects and blinding efficacy 12 
 13 
Tachycardia was the most frequently reported side effect in CAF (n = 9), followed by feelings of 14 
increased wakefulness and attention (n = 7). Despite this, only 17 participants correctly guessed the supplement 15 
ingested during both CAF and PLA. Moreover, 13 and 17 participants did not know what supplement they had 16 
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ingested during CAF and PLA. In addition, 12 and 8 participants incorrectly guessed the supplement ingested 17 
during CAF and PLA. Fisher's Exact Test did not show any significant differences between trials for the 18 
proportion of supplement identification (P = 0.57). Fisher’s Exact Test did not demonstrate any significant 19 
differences between low, moderate and high consumers for the reported side effects (P = 0.77). 20 
 21 
DISCUSSION 22 
 23 
 There has been a long-standing paradigm that habitual caffeine intake may influence the ergogenicity of 24 
caffeine supplementation. In contrast to this belief, this study showed that the level of habitual caffeine 25 
ingestion was not associated with the magnitude of improvement in cycling TT performance following acute 26 
caffeine supplementation.  27 
Caffeine supplementation improved exercise performance by 3.3% compared to CON and 2.4% 28 
compared to PLA. These data are in accordance with previous research, with meta-analytic data showing a 29 
mean overall improvement of 1.9% with caffeine.(11) However, individual responses to caffeine 30 
supplementation exist;(1) in our study, approximately half of the individuals improved above the variation of 31 
the test with caffeine. Habitual caffeine intake has been suggested as a potential factor underlying 32 
heterogeneous responses to this supplement.(5)  33 
It is known that caffeine acts on the central nervous system antagonizing the adenosine A1 and A2 34 
receptors, increasing circulating dopamine and noradrenaline.(27) Experimental data suggest that habitual 35 
intake of caffeine is associated with an increased regulation of the adenosine receptors.(12) In support of this 36 
notion, clinical studies have demonstrated a differential response to caffeine supplementation regarding mood 37 
and cognitive performance in low and high caffeine consumers.(2, 18) This suggests that habitual caffeine 38 
intake could influence exercise performance following caffeine supplementation, though current evidence is 39 
contrasting.(5, 10) Recently, Beaumont, et al.(4) showed that 4 weeks of caffeine supplementation induced a 40 
tolerance to the performance benefits of acute caffeine supplementation in low habitual caffeine consumers (< 41 
75 mg·day-1). However, the lack of a post-supplementation placebo trial, to provide a direct comparison with 42 
the post-supplementation caffeine trial does not allow conclusive interpretation of the results of this study. 43 
However, the relatively acute supplementation period (28 days) may have resulted in several acute adaptations 44 
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which do not represent chronic or habitual consumption. In the current study, there was no association between 45 
habitual caffeine intake and exercise improvements with caffeine supplementation. Furthermore, low, moderate 46 
and high consumers showed similar absolute and relative improvements in exercise performance. This concurs 47 
with previous findings suggesting no difference between high and low consumers concerning caffeine's ability 48 
to reduce muscle pain during cycling exercise, in which perceptions of pain and effort have been recognized as 49 
part of pacing strategies.(14)  50 
Divergent results seen in the literature could be partially explained by methodological differences. 51 
Firstly, previous studies employed capacity tests which are known to have limited external validity and high 52 
variability (>10%).(9, 20) We employed an exercise performance test with low variability (2.9%) in similarly 53 
trained participants.(28) Additionally, we allocated participants into tertiles according to their habitual caffeine 54 
intake as assessed by a validated FFQ method, resulting in distinct sub-groups with heterogeneous caffeine 55 
intake (i.e., low: 2 to 101; moderate: 104 to 183; high: 190 to 583 mg·day-1), allowing the investigation of a 56 
broad spectrum of habitual caffeine intake on exercise performance in response to caffeine supplementation. 57 
The calculated tertiles in this study are in agreement with the estimated average consumption of caffeine among 58 
the healthy population (mean: 165 mg·day-1; 90th percentile: 380 mg·day-1).(26) In contrast, other studies 59 
defined participants as caffeine consumers and naïve or non-consumers, without describing a method to support 60 
this approach of categorizing individuals on opposite ends of the spectrum (i.e., <50 or >300 mg·day-1).(5, 10) 61 
The widely differing range used to characterize habitual caffeine intake may have contributed to previous 62 
contrasting results. It also important to note that such a comprehensive comparison performed in the current 63 
study was only possible due to the large sample size (n = 40), which is higher than previous studies (17 – 21 64 
participants).(5, 10) In fact, this large sample allowed us to further explore our hypothesis a posteriori by 65 
allocating participants into quartiles and quintiles, with still no significant differences between them in relation 66 
to performance (data not shown).  67 
Athletes are commonly encouraged to refrain from caffeinated products for up to 4 days before 68 
supplementing with caffeine to enhance the efficacy of acute supplementation.(31) Despite this, Irwin, et al.(21) 69 
showed similar improvements in exercise with caffeine in habitual consumers regardless of a 4 day withdrawal 70 
period. Similarly, Van Soeren, et al.(35) showed equal exercise improvements with acute caffeine 71 
supplementation in habituated consumers following no, 2-days and 4-days of caffeine withdrawal. In the 72 
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current study, to control the protocol, individuals were asked to refrain from caffeine only in the 24-h prior to 73 
exercise. It could be suggested that this period of withdrawal may have created an artefact by “normalising” the 74 
recent caffeine history of the participants. However, sudden caffeine cessation is unlikely to lead to withdrawal 75 
symptoms, any of which are likely only to be moderate,(27) while the previously mentioned studies showed 76 
that up to 4 days of caffeine withdrawal do not influence the exercise responses to an acute dose of caffeine 77 
supplementation in habitual caffeine consumers.(21, 35) Therefore, we are satisfied that our methodology was 78 
sufficient to test our initial hypothesis, although future research investigating the effects of habitual 79 
consumption should perhaps record, and not prohibit, caffeine consumption in the 24 h preceding exercise.  80 
At doses of 3-9 mg·kg-1BM, caffeine is known to induce specific side effects, such as tachycardia, 81 
anxiety, gastrointestinal discomfort, tremors, and insomnia.(17) It is believed that habitual caffeine consumers 82 
are less susceptible to these side-effects at the same relative doses when compared to non-consumers.(15) 83 
However, when participants were asked about the perceived effects 60-min after acute supplementation, they 84 
reported the same side effects regardless of habitual caffeine intake. These results reinforce the notion that the 85 
perceptual and exercise individual responses to caffeine may be triggered by other factors, such as genetics, 86 
rather than habitual caffeine intake per se. In fact, genome-wide association studies have suggested that single 87 
nucleotide polymorphisms in genes related to caffeine metabolism (aryl-hydrocarbon receptor [AHR], 88 
cytochrome P450 1A1 and 1A2 [CYP1A1-CYP1A2, Prenyl (Decaprenyl) Diphosphate Synthase, Subunit 2 89 
associated with habitual caffeine and coffee consumption.(23, 29) If the grouping of individuals in the current 90 
study reflect different polymorphisms of various caffeine-related genes, then our data would challenge the 91 
notion that certain genotypes result in carry over effects to performance. However, this is highly speculative 92 
since genotypic analysis was beyond the scope of this study though further studies assessing caffeine-related 93 
polymorphisms and exercise are warranted. 94 
A limitation of this study is that we were unable to measure blood caffeine concentrations. However, all 95 
previous studies employing doses of 3-9 mg·kg-1BM 60-min before a given exercise task have reported 96 
significant increases in caffeine concentration.(17, 34) Therefore, it can be assumed that our supplementation 97 
protocol was effective in increasing blood caffeine levels. Furthermore, these findings must be confined to male 98 
participants, since sexual dimorphism seems to exist in response.(33) We ensured tight control of our 99 
experimental measures by having individuals attend the laboratory following a 6-h fast and 24-h post-caffeine 00 
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(and alcohol) ingestion. We acknowledge, however, that exercising in a fasted state does not represent the 01 
recommendations of current sports nutrition guidelines or the “real life” practices of cyclists, nor does a 02 
withdrawal period appear necessary to elicit performance improvements following acute caffeine 03 
supplementation.(21) Although a 6 mg·kg-1BM was employed in this study, we acknowledge that 3 mg·kg-1BM 04 
is sufficient to induce performance effects.(17) 05 
In conclusion, performance benefits with acute caffeine supplementation during a ~30 min cycling TT 06 
were not influenced by the level of habitual caffeine consumption, refuting the long-standing notion that 07 
habitual caffeine intake may negatively affect exercise performance in response to caffeine supplementation.  08 
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AB
C
Figure 1: Panel A: Time-trial performance with caffeine (CAF), placebo (PLA) or no supplement
(CON) * indicates significant difference (P < 0.05) compared to PLA and CON. Panel B: Rating of
perceived exertion throughout the simulated time-trial with caffeine (CAF), placebo (PLA) or no
supplement (CON). * indicates significant difference (P < 0.05) compared to the previous stage.
Panel C: Plasma lactate (mmol.L-1) throughout exercise with caffeine (CAF), placebo (PLA) or no
supplement (CON). * indicates significant difference (P < 0.05) compared to the previous stage.
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Figure 2: Panel A: Time-trial performance in caffeine (CAF), placebo (PLA)
or no supplement (CON) separated according to habitual caffeine intake (P >
0.05). Panel B: Absolute change (compared to CON) in time-trial
performance after caffeine (CAF) or placebo (PLA) separated according to
habitual caffeine intake (P > 0.05).
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Figure 3: Individual relative change in time-trial performance in CAF vs. CON for low, moderate and
high consumers. The black dashed line represents the natural variation of the test (±3.0%); the grey
dashed line represents the mean overall improvement with caffeine (+3.3%). The number of individuals
who improved above, were within, or worsened beyond the natural variation of the test in each sub-group
is displayed below the graph (P>0.05).
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Figure 4: Correlation between habitual caffeine intake and absolute change in
exercise performance in CAF vs. CON (P > 0.05).
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Table 1. Participant characteristics 
  Low  Moderate  High  
Mean (SD) (n=14) (n=12) (n=14) 
Age 34 ± 9 37 ± 7 37 ± 8 
Height (m) 1.74 ± 0.08 1.77 ± 0.05 1.77 ± 0.03 
Weight (kg) 72.08 ± 11.13 74.95 ± 4.92 76.05 ± 8.42 
VO2max (ml.kg-1.min-1) 50.10 ± 8.45 51.00 ± 6.08 50.90 ± 7.54 
Caffeine intake (mg/day)* 58 ± 29 143 ± 25       351 ± 139 
Low, moderate and high = habitual caffeine intake 
*Significant difference between tertiles (P < 0.05) 
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Table 2.  Magnitude-based inferences for time-trial performance across tertiles 
 
  Difference (%) Chances of treatment Chances of treatment Chances of  treatment being 
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 being positive (%) being trivial (%) negative (%) 
Low 
CAF vs CON -3.71 ± 7.62 82 17 1 
CAF vs. PLA -1.57 ± 4.25 51 49 0 
     PLA VS. CON 
                      
1.50 ± 15.25            53 44 3 
Moderate  
CAF vs CON -4.57 ± 3.63 99 1 0 
CAF vs. PLA -3.69 ± 4.65 93 6 1 
PLA vs. CON -0.28 ± 9.83 40 53 7 
High 
CAF vs. CON       -0.88 ± 7.85 49 46 5 
CAF vs. PLA -1.4 ± 7.68 55 43 2 
PLA vs. CON -1,38 ± 13,77 14 66 20 
Legend: CON = control, PLA = placebo; CAF = caffeine 
Low, moderate and high = habitual caffeine intake 
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Table 3: Food consumption data of participants prior to the experimental sessions. 
  CON PLA CAF 
Low Moderate High Low Moderate High Low Moderate High 
Protein (g) 114 ± 42 114 ± 36 123 ± 46 122 ± 61 99 ± 37 105 ± 59 114 ± 59 104 ± 64 128 ± 58 
Carbohydrate (g) 360 ± 89 347 ± 105 334 ± 144 354 ± 108 295 ± 76 306 ± 164 357 ± 132 351 ± 151 319 ± 222 
Fat (g) 82 ± 21 80 ± 29 77 ± 22 87 ± 36 66 ± 25 80 ± 46  86 ± 30  74 ± 46 84 ± 28 
Caloric intake (kcal) 2548 ± 553 2711 ± 1116 2631 ± 1045 2708 ± 716 2338 ± 504 2383 ± 1032 2637 ± 877 2474 ± 1062 2628 ± 1051 
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